Better HIV and malaria treatment for people in Africa
Optimizing HIV-malaria treatment in a shifting treatment and resistance landscape in Africa
This project looks at how common HIV medicine dolutegravir and standard malaria drugs work together in children and adults in sub‑Saharan Africa to keep treatments safe and effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11375255 on NIH RePORTER |
What this research studies
I would be followed at clinics in sub‑Saharan Africa if I join, including children and adults who have HIV and may get malaria. The team will track changes in weight and metabolism on dolutegravir and will take blood samples to measure levels of malaria drugs when people take both medicines. They will record side effects, drug levels, and health outcomes over time to see if dosing or combinations need to be changed. The work aims to find treatment approaches that avoid reduced drug levels or overlapping harms when HIV and malaria medicines are used together.
Who could benefit from this research
Good fit: Ideal candidates are children, adolescents, and adults living with HIV in sub‑Saharan Africa who are taking or likely to start dolutegravir‑based therapy and who are at risk of or being treated for malaria.
Not a fit: People without HIV, those not taking dolutegravir, or people living outside the study regions are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could lead to safer dosing and treatment combinations that reduce side effects and keep both HIV and malaria drugs working well for patients.
How similar studies have performed: Earlier studies have shown dolutegravir can change levels of some malaria partner drugs, but pediatric data and evidence for commonly used combinations are limited.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Parikh, Sunil — Yale University
- Study coordinator: Parikh, Sunil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.